The lung cancer patient quality of life during the first line of treatment – multicenter prospective data
Authors:
M. Bratová 1; L. Jakubíková 2,3; J. Kultan 4; M. Svaton 5; M. Svoboda 6; K. Brat 1,3
Authors‘ workplace:
Klinika komplexní onkologické péče LF MU a MOÚ Brno
1; Klinika nemocí plicních a tuberkulózy LF MU a FN Brno
2; Centrum pneumologie a intervenční bronchologie, MOÚ Brno
3; Klinika plicních nemocí a tuberkulózy LF UP a FN Olomouc
4; Klinika pneumologie a ftizeologie LF v Plzni UK a FN Plzeň
5; Institut biostatistiky a analýz, s. r. o, Brno
6
Published in:
Klin Onkol 2025; 38(2): 97-103
Category:
Original Articles
doi:
https://doi.org/10.48095/ccko202597
Overview
Introduction: Despite of a progress in anticancer treatment in the last decades, quality of life (QoL) of these patients is still very poor. The aim of this study was to monitor QoL during the first line of modern era treatment in lung cancer patients in Czechia. Material and methods: It is a prospective multicenter study realized at three pneumo-oncology departments of University Hospitals in Brno, Olomouc and Pilsen. In the period of time from April to August 2023 we asked patients with non-small cell lung cancer starting the first line of anticancer treatment to fill the questionnaire of QoL “EQRTC QoL-C30” in the time 0 and 6 and 12 weeks. Results: We studied data from 50 patients, 60% men, the average age 66,9 years, 76% smokers, 22% in stage III, 78% in stage IV, 84% non-small cell lung cancer, 16% small cell lung cancer. A total of 50% patients were treated with chemoimmunotherapy, 20% by immunotherapy, 24% by chemotherapy +/− irradiation, and 6% by tyrosine kinase inhibitors. There was a significant improvement of QoL in the mean of dyspnoe, weakness, depression and fear during the treatment. In the subgroup analysis, patients treated with chemo/immunotherapy reached an improvement in total QoL. Subjects with complete/partial response to treatment reached improvement in some aspects of QoL. Out of laboratory parameters, albumin levels were associated with QoL. Conclusion: QoL of patients with lung cancer treated with first-line anticancer treatment in the Czech real-life practice is acceptable.
Keywords:
lung cancer – Quality of life – oncological treatment
Sources
1. WHO. WHOQOL: measuring quality of life. 2025 [online]. Available from: https: //www.who.int/tools/whoqol.
2. IARC. Cancer today 2022. 2025 [online]. Available from: https: //gco.iarc.fr/today/en/dataviz/pie?mode=cancer &group_populations=1&types=1.
3. Zabora J, BrintzenhofeSzoc K, Curbow B et al. The prevalence of psychological distress by cancer site. Psychooncology 2001; 10 (1): 19–28. doi: 10.1002/1099-1611 (200101/02) 10: 1<19:: aid-pon501>3.0.co; 2-6.
4. ÚZIS. Novotvary 2019–2021. 2025 [online]. Dostupné z: https: //www.uzis.cz/res/f/008447/novotvary2019-2021.pdf.
5. Sanders SL, Bantum EO, Owen JE et al. Supportive care needs in patients with lung cancer. Psychooncology 2010; 19 (5): 480–489. doi: 10.1002/pon.1577.
6. Carlsen K, Jensen AB, Jacobsen E et al. Psychosocial aspects of lung cancer. Lung Cancer 2005; 47 (3): 293–300. doi: 10.1016/j.lungcan.2004.08.002.
7. Bratova M, Karlinova B, Skrickova J et al. Non-small cell lung cancer as a chronic disease – a prospective study from the Czech TULUNG registry. In Vivo 2020; 34 (1): 369–379. doi: 10.21873/invivo.11783.
8. Solomon BJ, Liu G, Felip E et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. J Clin Oncol 2024; 42 (29): 3400–3409. doi: 10.1200/JCO.24.00581.
9. Zhou C, Lu Y, Kim SW et al. Alectinib versus crizotinib in Asian patients with treatment-Naïve advanced ALK--positive NSCLC: five-year update from the phase 3 ALESIA study. JTO Clin Res Rep 2024; 5 (9): 100700. doi: 10.1016/j.jtocrr.2024.100700.
10. Landre T, Assié JB, Chouahnia K et al. First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials. Expert Rev Anticancer Ther 2024; 24 (8): 775–780. doi: 10.1080/14737140.2024.2362889.
11. Reck M, Rodríguez-Abreu D, Robinson AG et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol 2021; 39 (21): 2339–2349. doi: 10.1200/JCO.21.00174.
12. Garassino MC, Gadgeel S, Esteban E et al. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21 (3): 387–397. doi: 10.1016/S1470-2045 (19) 30801-0.
13. Amari L, Tomasini P, Dantony E et al. Safety and patient-reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study). Lung Cancer 2024; 193: 107843. doi: 10.1016/j.lungcan.2024.107843.
14. Raez LE, Kang H, Ohe Y et al. Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial. ESMO Open 2024; 9 (5): 103444. doi: 10.1016/j.esmoop.2024.103444.
15. Morrison EJ, Novotny PJ, Sloan JA et al. Emotional problems, quality of life, and symptom burden in patients with lung cancer. Clin Lung Cancer 2017; 18 (5): 497–503. doi: 10.1016/j.cllc.2017.02.008.
16. Brett BC, Zhao J, Li F et al. Trends and predictors of quality of life in lung cancer survivors. Lung Cancer 2024; 191: 107793. doi: 10.1016/j.lungcan.2024.107793.
17. Urata A. Prognostic factors in unresectable lung cance. Gan To Kagaku Ryoho 1988; 15 (7): 2035–2042.
18. Lucas-Ruano D, Sanchez-Gomez C, Rihuete-Galve MI et al. Descriptive study on the relationship between dyspnea, physical performance, and functionality in oncology patients. Healthcare 2024; 12 (16): 1675. doi: 10.3390/healthcare12161675.
19. Liu J, Cheng W, Du J et al. Early palliative care in advanced non-small cell lung cancer patients: a meta-analysis. Am J Hosp Palliat Care 2024; 10499091241300530. doi: 10.1177/10499091241300530.
20. Shiraishi Y, Nomura S, Sugawara S et al. Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial. Lancet Respir Med 2024; 12 (11): 877–887. doi: 10.1016/S2213-2600 (24) 00185-1.
21. Berardi R, Santoni M, Rinaldi S et al. Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer. Ann Transl Med 2019; 7 (20): 572. doi: 10.21037/atm.2019.09.18.
22. Liu Q, He J, Ning R et al. Pretreatment plasma d-dimer levels as an independent prognostic factor for overall survival among patients with advanced non-small-cell lung cancer. J Int Med Res 2020; 48 (10): 300060520962661. doi: 10.1177/0300060520962661.
23. Zhou S, Jiang W, Wang H et al. Predictive value of pretreatment albumin-to-alkaline phosphatase ratio for overall survival for patients with advanced non-small cell lung cancer. Cancer Med 2020; 9 (17): 6268–6280. doi: 10.1002/cam4.3244.
24. Ma K, Xu W, Wang C et al. Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first- -line chemotherapy. Cancer Biomark 2017; 18 (3): 297–303. doi: 10.3233/CBM-161687.
25. Fiala O, Pesek M, Finek J et al. Prognostic significance of serum tumor markers in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy. Anticancer Res 2016; 36 (1): 461–466.
26. Meyo MT, Boudou-Rouquette P, Arrondeau J et al. Relationship between energetic gap and sensitivity to anti-programmed cell death 1 immune checkpoint inhibitors in non-small cell lung cancer patients: the ELY-2 study. Clin Nutr ESPEN 2024; 64: 44–50. doi: 10.1016/j.clnesp.2024.09.002.
27. Bilgin B, Kuralay Y, Yucel S. Prognostic importance of prognostic nutritional index and modified Glasgow prognostic score in advanced lung cancer with targetable mutation. J Cancer Res Clin Oncol 2024; 150 (4): 215. doi: 10.1007/s00432-023-05529-w.
28. Lei W, Wang W, Qin S et al. Predictive value of inflammation and nutritional index in immunotherapy for stage IV non-small cell lung cancer and model construction. Sci Rep 2024; 14 (1): 17511. doi: 10.1038/s41598-024-66813-4.
29. Bergerot PG, Bergerot CD, Silva JRG et al. Exercising and immuno-oncology treatment (ExIO): a prospective pilot study for patients with solid tumors. Support Care Cancer 2024; 32 (12): 840. doi: 10.1007/s00520-024- 09056-3.
30. Soria-Comes T, Climent-Gregori M, Maestu-Maiques I et al. Effect of a physical exercise intervention on physical function parameters and blood analytical changes in lung cancer survivors: a feasibility study. Clin Pract 2024; 14 (5): 2202–2216. doi: 10.3390/clinpract14050173.
31. Bennati C, Ferrara R, Sangaletti S et al. The EXcellenT trial: exercise in extended oncogene addicted lung cancer in active treatment. Clin Lung Cancer 2024; 25 (8): e397–e401. doi: 10.1016/j.cllc.2024.07.008.
32. Kirkpatrick S, Davey Z, Wright PR et al. Supportive eHealth technologies and their effects on physical functioning and quality of life for people with lung cancer: systematic review. J Med Internet Res 2024; 26: e53015. doi: 10.2196/53015.
33. Greer JA, Temel JS, El-Jawahri A et al. Telehealth vs in-person early palliative care for patients with advanced lung cancer: a multisite randomized clinical trial. JAMA 2024; 332 (14): 1153–1164. doi: 10.1001/jama.2024.13964.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2025 Issue 2
Most read in this issue
- Ivosidenib in the treatment of metastatic cholangiocarcinoma – a case report
- Napřimování čili rektifikace trajektorií v onkologii
- Cemiplimab in the treatment of non-small cell lung cancer
- The lung cancer patient quality of life during the first line of treatment – multicenter prospective data